• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

述评:阿杜卡奴单抗相关 ARIA:赞歌还是悲歌?

Commentary: Aducanumab-Related ARIA: Paean or Lament?

机构信息

From the Department of Radiology, Keck School of Medicine of USC, Los Angeles, CA.

出版信息

Clin Nucl Med. 2022 Aug 1;47(8):707-709. doi: 10.1097/RLU.0000000000004252. Epub 2022 May 11.

DOI:10.1097/RLU.0000000000004252
PMID:35543641
Abstract

Høilund-Carlsen and colleagues raise important issues related to amyloid PET, diagnosis of Alzheimer disease, and recently approved antiamyloid treatment aducanumab. We discuss new developments that may direct us to methods of presymptomatic detection of Alzheimer disease and development of effective prevention and therapy.

摘要

霍尔伦德-卡尔森(Høilund-Carlsen)及其同事提出了与淀粉样蛋白 PET、阿尔茨海默病诊断以及最近批准的抗淀粉样蛋白治疗药物 aducanumab 相关的重要问题。我们讨论了新的发展,这些发展可能会引导我们找到阿尔茨海默病的无症状检测方法,并开发有效的预防和治疗方法。

相似文献

1
Commentary: Aducanumab-Related ARIA: Paean or Lament?述评:阿杜卡奴单抗相关 ARIA:赞歌还是悲歌?
Clin Nucl Med. 2022 Aug 1;47(8):707-709. doi: 10.1097/RLU.0000000000004252. Epub 2022 May 11.
2
Re: Aducanumab-Related ARIA: Paean or Lament?关于:与阿杜卡单抗相关的淀粉样蛋白相关成像异常(ARIA):赞歌还是挽歌?
Clin Nucl Med. 2023 Feb 1;48(2):168-169. doi: 10.1097/RLU.0000000000004490. Epub 2022 Nov 11.
3
Aducanumab-Related Amyloid-Related Imaging Abnormalities: Paean or Lament?阿杜卡奴单抗相关淀粉样蛋白相关影像学异常:赞歌还是悲歌?
Clin Nucl Med. 2022 Jul 1;47(7):625-626. doi: 10.1097/RLU.0000000000004250. Epub 2022 Apr 22.
4
Re: Aducanumab-Related ARIA: Paean or Lament?关于:与阿杜卡单抗相关的淀粉样蛋白相关成像异常(ARIA):赞歌还是挽歌?
Clin Nucl Med. 2023 Jun 1;48(6):505-506. doi: 10.1097/RLU.0000000000004509. Epub 2023 Feb 1.
5
Amyloid-Related Imaging Abnormalities in 2 Phase 3 Studies Evaluating Aducanumab in Patients With Early Alzheimer Disease.在两项评估早期阿尔茨海默病患者使用 aducanumab 的 3 期研究中,淀粉样蛋白相关成像异常。
JAMA Neurol. 2022 Jan 1;79(1):13-21. doi: 10.1001/jamaneurol.2021.4161.
6
Alzheimer disease neuropathology in a patient previously treated with aducanumab.阿杜卡努单抗治疗后的阿尔茨海默病患者的神经病理学。
Acta Neuropathol. 2022 Jul;144(1):143-153. doi: 10.1007/s00401-022-02433-4. Epub 2022 May 17.
7
Initial Experiences with Amyloid-Related Imaging Abnormalities in Patients Receiving Aducanumab Following Accelerated Approval.接受加速批准的 aducanumab 治疗后出现淀粉样蛋白相关影像学异常的初步经验。
J Prev Alzheimers Dis. 2023;10(4):765-770. doi: 10.14283/jpad.2023.96.
8
A Time-to-Event Exposure-Response Model for Amyloid-Related Imaging Abnormalities Following Administration of Aducanumab to Subjects With Early Alzheimer Disease.在早期阿尔茨海默病患者中使用 aducanumab 后,淀粉样蛋白相关影像学异常的时间事件暴露-反应模型。
J Clin Pharmacol. 2022 Aug;62(8):1030-1046. doi: 10.1002/jcph.2047. Epub 2022 Apr 4.
9
Amyloid-related Imaging Abnormalities in Alzheimer Disease Treated with Anti-Amyloid-β Therapy.阿尔茨海默病患者接受抗β淀粉样蛋白治疗后的淀粉样相关影像学异常。
Radiographics. 2023 Sep;43(9):e230009. doi: 10.1148/rg.230009.
10
Aducanumab: The first targeted Alzheimer's therapy.阿杜卡努单抗:首款靶向阿尔茨海默病疗法。
Drug Discov Ther. 2021;15(3):166-168. doi: 10.5582/ddt.2021.01061.

引用本文的文献

1
FDG-PET versus Amyloid-PET Imaging for Diagnosis and Response Evaluation in Alzheimer's Disease: Benefits and Pitfalls.18F-氟脱氧葡萄糖正电子发射断层扫描(FDG-PET)与淀粉样蛋白正电子发射断层扫描(Amyloid-PET)在阿尔茨海默病诊断及疗效评估中的应用:优势与局限
Diagnostics (Basel). 2023 Jul 3;13(13):2254. doi: 10.3390/diagnostics13132254.
2
Photobiomodulation in Alzheimer's Disease-A Complementary Method to State-of-the-Art Pharmaceutical Formulations and Nanomedicine?阿尔茨海默病中的光生物调节——一种现有药物制剂和纳米医学的补充方法?
Pharmaceutics. 2023 Mar 11;15(3):916. doi: 10.3390/pharmaceutics15030916.